Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner.
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
23
02
2018
accepted:
24
07
2018
revised:
27
06
2018
pubmed:
5
9
2018
medline:
27
2
2019
entrez:
5
9
2018
Statut:
ppublish
Résumé
Heterogeneous prostatic carcinoma-associated fibroblasts (CAF) contribute to tumor progression and resistance to androgen signaling deprivation therapy (ADT). CAF subjected to extended passaging, compared to low passage CAF, were found to lose tumor expansion potential and heterogeneity. Cell surface endoglin (CD105), known to be expressed on proliferative endothelia and mesenchymal stem cells, was diminished in high passage CAF. RNA-sequencing revealed SFRP1 to be distinctly expressed by tumor-inductive CAF, which was further demonstrated to occur in a CD105-dependent manner. Moreover, ADT resulted in further expansion of the CD105
Identifiants
pubmed: 30177832
doi: 10.1038/s41388-018-0461-3
pii: 10.1038/s41388-018-0461-3
pmc: PMC7182071
mid: NIHMS1500953
doi:
Substances chimiques
ENG protein, human
0
Endoglin
0
Neoplasm Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
716-730Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK007770
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : CA108646
Pays : International
Organisme : NCI NIH HHS
ID : P01 CA098912
Pays : United States
Organisme : U.S. Department of Veterans Affairs (VA)
ID : BX001040
Pays : International
Organisme : U.S. Department of Defense (DOD)
ID : PC160946
Pays : International
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : CA098912
Pays : International
Organisme : NCI NIH HHS
ID : R01 CA108646
Pays : United States
Organisme : BLRD VA
ID : I01 BX001040
Pays : United States
Organisme : U.S. Department of Defense (DOD)
ID : PC161016
Pays : International
Références
Carcinogenesis. 2016 Jul;37(7):701-711
pubmed: 27207661
J Natl Cancer Inst. 2015 May 08;107(8):
pubmed: 25956356
Nihon Hinyokika Gakkai Zasshi. 2016;107(3):155-161
pubmed: 28740046
Prostate. 2015 Jan;75(1):84-91
pubmed: 25307287
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Dev Biol. 2008 May 1;317(1):161-73
pubmed: 18371946
PLoS One. 2011;6(6):e20412
pubmed: 21673995
BJU Int. 2015 Oct;116(4):546-55
pubmed: 25407442
Cancer Cell. 2013 Mar 18;23(3):332-46
pubmed: 23518348
Prostate. 2017 Nov;77(15):1489-1498
pubmed: 28905415
PLoS One. 2013 Jun 24;8(6):e66855
pubmed: 23826159
Cancer Res. 2005 Nov 15;65(22):10423-30
pubmed: 16288033
Nat Cell Biol. 2013 Jul;15(7):807-17
pubmed: 23728425
Br J Cancer. 2011 Sep 27;105(7):996-1001
pubmed: 21863023
Oncology (Williston Park). 2017 Jun 15;31(6):467-74
pubmed: 28620903
Cancer. 2017 Dec 15;123(24):4770-4790
pubmed: 29112233
Cancer Res. 1991 Jul 15;51(14):3753-61
pubmed: 1712249
PLoS One. 2015 Feb 26;10(2):e0118276
pubmed: 25719802
Cancer. 2005 Dec 1;104(11):2292-309
pubmed: 16258976
Oncotarget. 2016 Sep 27;7(39):64447-64470
pubmed: 27487144
Am J Transl Res. 2009 Jan 20;1(2):115-30
pubmed: 19956425
Br J Cancer. 2009 Apr 7;100(7):1165-74
pubmed: 19277043
Mod Pathol. 2010 Oct;23(10):1346-56
pubmed: 20562849
Oncogene. 2014 Oct 9;33(41):4924-31
pubmed: 24141771
Clin Cancer Res. 2003 Oct 15;9(13):4792-801
pubmed: 14581350
EMBO Rep. 2013 Aug;14(8):686-95
pubmed: 23846313
Development. 2011 Oct;138(19):4179-84
pubmed: 21896628
Prostate. 2009 Jun 15;69(9):991-1000
pubmed: 19267366
Oncogene. 2016 Aug 18;35(33):4321-34
pubmed: 26751775
Cancer Res. 1999 Oct 1;59(19):5002-11
pubmed: 10519415
J Clin Oncol. 2012 Dec 20;30(36):e386-9
pubmed: 23169519
Cancer Res. 2001 Nov 15;61(22):8135-42
pubmed: 11719442
PLoS One. 2012;7(12):e50920
pubmed: 23300529
Cancer Res. 2008 Jun 15;68(12):4709-18
pubmed: 18559517
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15548-53
pubmed: 14657354
Science. 2017 Jan 6;355(6320):84-88
pubmed: 28059768
Science. 2004 Feb 6;303(5659):848-51
pubmed: 14764882
Cancer Res. 2011 May 15;71(10):3459-70
pubmed: 21444670
Cancer Res. 2011 Feb 15;71(4):1272-81
pubmed: 21303979
Cancer Discov. 2011 Nov;1(6):487-95
pubmed: 22389870
Oncogene. 2008 Nov 27;27(56):7118-30
pubmed: 18724388
Oncotarget. 2013 Jan;4(1):106-17
pubmed: 23362217
Prostate. 2013 Jun;73(9):979-85
pubmed: 23371521
J Invest Dermatol. 1999 May;112(5):681-91
pubmed: 10233757
Cancer Res. 2011 May 15;71(10):3482-93
pubmed: 21444673
Oncogene. 2003 Sep 29;22(42):6557-63
pubmed: 14528280
Breast Cancer Res. 2016 Aug 11;18(1):84
pubmed: 27515302
J Cell Sci. 2008 Mar 15;121(Pt 6):737-46
pubmed: 18322270